8.1 Acute Coronary Syndromes (ACS) & Heart Failure

7.1 Acute Coronary Syndromes (ACS) & Heart Failure

Cardiovascular disease represents one of the primary causes of emergency hospital admissions and mortality in Ireland. Registered General Nurses (RGNs) practicing in acute admissions units, emergency departments, coronary care units (CCUs), and medical wards must possess advanced clinical competency in recognizing acute myocardial ischemia, interpreting diagnostic biomarkers and 12-lead electrocardiograms (ECGs), executing rapid pharmacological interventions, and managing complex heart failure decompensation. This section synthesizes the pathophysiology, diagnostic criteria, acute emergency protocols, reperfusion pathways, and long-term nursing management of Acute Coronary Syndromes (ACS) and Heart Failure (HF), drawing on European Society of Cardiology (ESC) guidelines and Health Service Executive (HSE) national clinical care programmes.

---

1. The Acute Coronary Syndrome (ACS) Spectrum & Atherothrombosis

Acute Coronary Syndrome (ACS) is an umbrella term encompassing three distinct life-threatening clinical entities characterized by acute myocardial ischemia:

1. Unstable Angina (UA)
2. Non-ST-Elevation Myocardial Infarction (NSTEMI)
3. ST-Elevation Myocardial Infarction (STEMI)

+-----------------------------------------------------------------------------+
|                     ACUTE CORONARY SYNDROMES (ACS) SPECTRUM                 |
+-----------------------------------------------------------------------------+
|                                                                             |
|             CORONARY ATHEROSCLEROTIC PLAQUE INSTABILITY & RUPTURE           |
|                                     │                                       |
|                                     ▼                                       |
|             PLATELET ADHESION, ACTIVATION & THROMBUS FORMATION              |
|                                     │                                       |
|         ┌───────────────────────────┴───────────────────────────┐           |
|         ▼                                                       ▼           |
|  PARTIAL / TRANSIENT OCCLUSION                         COMPLETE OCCLUSION   |
|  (Subendocardial Ischemia)                             (Transmural Necrosis)|
|         │                                                       │           |
|   ┌─────┴──────────────┐                                        │           |
|   ▼                    ▼                                        ▼           |
| UNSTABLE ANGINA     NSTEMI                                    STEMI         |
| - Normal Troponin   - Dynamic Troponin Rise/Fall       - Persistent ST      |
| - ST depression /   - ST depression / T inversion        Elevation or LBBB  |
|   T-wave inversion  - Subendocardial necrosis          - Positive Troponin  |
| - No necrosis       - High ischaemic risk              - Transmural infarct |
+-----------------------------------------------------------------------------+

Pathophysiology of Atherothrombosis

• Atherosclerotic Plaque Formation: Chronic endothelial injury—fueled by smoking, hypertension, dyslipidemia, diabetes mellitus, and systemic inflammation—permits low-density lipoprotein (LDL) cholesterol to infiltrate the coronary tunica intima. LDL undergoes oxidation, triggering an innate immune response where monocyte-derived macrophages engulf oxidized lipids to become lipid-laden foam cells. The coalescence of foam cells creates a fatty streak, which subsequently stimulates smooth muscle proliferation and collagen deposition, forming a fibroatheromatous plaque with a necrotic lipid core covered by a fibrous cap.
• Plaque Disruption & Rupture: Activated macrophages and T-lymphocytes within the plaque secrete matrix metalloproteinases (MMPs) that degrade extracellular collagen, thinning the fibrous cap. Under hemodynamic shear stress, the fragile cap ruptures or erodes, exposing highly thrombogenic subendothelial collagen and von Willebrand factor (vWF) to circulating blood.
• Platelet Cascade & Thrombosis:
  1. Platelet Adhesion: Circulating platelets bind to exposed subendothelial vWF via glycoprotein Ib/IX (GP Ib/IX) receptors.
  2. Platelet Activation: Adherent platelets undergo shape change and degranulate, releasing adenosine diphosphate (ADP), thromboxane A2 (TxA2), and serotonin. These autocrine and paracrine mediators recruit additional circulating platelets.
  3. Platelet Aggregation: Activation induces a conformational change in platelet surface Glycoprotein IIb/IIIa (GP IIb/IIIa) receptors, enabling circulating divalent fibrinogen molecules to bridge adjacent platelets, generating an unstable "white" platelet thrombus.
  4. Coagulation Cascade Activation: Tissue factor exposed at the rupture site triggers the extrinsic coagulation cascade, generating thrombin (Factor IIa). Thrombin cleaves fibrinogen into insoluble fibrin strands, which enmesh red blood cells to stabilize the thrombus into an occlusive "red" clot.
• Myocardial Necrosis: When coronary arterial perfusion ceases, intracellular glycogen stores are depleted within seconds, oxidative phosphorylation halts, and anaerobic glycolysis generates intracellular lactic acidosis. Within 20 to 30 minutes of complete, unmitigated ischemia, irreversible myocardial cell death (coagulative necrosis) begins in the subendocardium and progresses wave-like toward the epicardium, culminating in transmural infarction unless reperfusion is rapidly re-established.

---

2. Diagnostic Triad: Clinical Presentation, Biomarkers & ECG Criteria

The clinical differentiation of ACS relies on three interdependent diagnostic pillars: presenting symptoms, dynamic cardiac biomarkers, and 12-lead electrocardiography.

Clinical Presentation

• Typical Ischemic Chest Pain: Severe, retrosternal or precordial crushing, heavy, squeezing, or tight chest pain lasting >20 minutes. Radiation typically involves the left arm, shoulder, neck, mandible, epigastrium, or interscapular region. Associated autonomic symptoms include diaphoresis, pallor, nausea, vomiting, presyncope, and profound dyspnea.
• Atypical Presentations ("Silent Ischemia"): Female patients, older adults (>75 years), and patients with long-standing diabetes mellitus (due to diabetic autonomic neuropathy) frequently present without classic crushing retrosternal pain. Atypical equivalents include isolated dyspnea, unexplained acute fatigue, epigastric discomfort mimicking indigestion, acute confusion, or sudden hemodynamic collapse. Under Irish National Early Warning Score (INEWS v2) protocols, any unexplained acute physiological deterioration warrants an immediate 12-lead ECG.

Cardiac Biomarkers: High-Sensitivity Troponin Kinetics

Cardiac troponins—specifically high-sensitivity cardiac Troponin T (hs-cTnT) and high-sensitivity cardiac Troponin I (hs-cTnI)—are structural proteins unique to cardiac myocytes that regulate calcium-mediated actin-myosin cross-bridging.

• Diagnostic Sensitivity: High-sensitivity assays detect picogram concentrations of troponin released into the systemic circulation following myocyte sarcolemmal disruption. A diagnosis of myocardial infarction requires a dynamic rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit (URL) of a healthy reference population, in the context of clinical evidence of acute myocardial ischemia.
• Release Kinetics: Hs-cTn begins rising in peripheral blood within 2 to 4 hours post-injury, reaches peak concentrations at 12 to 24 hours, and remains elevated for 10 to 14 days due to the slow degradation of structurally bound myofilaments. Serial testing (at baseline / 0 hours, followed by 1-hour or 3-hour post-admission re-testing according to ESC accelerated diagnostic pathways) is mandatory to demonstrate dynamic elevation and differentiate acute infarction from chronic baseline troponin elevation (such as in chronic kidney disease or structural heart failure).
• Troponin vs. Other Markers: Creatine Kinase-MB (CK-MB) rises within 4 to 6 hours and normalizes within 48 to 72 hours; while obsolete for primary diagnosis, it remains clinically useful for detecting early re-infarction occurring within the 14-day window of troponin persistence. Myoglobin rises within 1 to 2 hours but lacks myocardial tissue specificity.

12-Lead ECG Diagnostic Criteria & Contiguous Leads

A 12-lead ECG must be acquired and interpreted by a competent clinician within 10 minutes of first medical contact (FMC) or emergency presentation.

• STEMI Diagnostic Thresholds (at the J-point in ≥2 contiguous leads):
  • Limb Leads (I, II, III, aVR, aVL, aVF): New ST-segment elevation $\ge 1\text{ mm}$ (0.1 mV).
  • Precordial Leads V2–V3: New ST-segment elevation $\ge 2.5\text{ mm}$ in men <40 years; $\ge 2.0\text{ mm}$ in men $\ge 40$ years; or $\ge 1.5\text{ mm}$ in women of any age.
  • Precordial Leads V1, V4, V5, V6: New ST-segment elevation $\ge 1\text{ mm}$ (0.1 mV).
  • New or Presumed New Left Bundle Branch Block (LBBB): Accompanied by ischemic symptoms must be treated as a STEMI equivalent.
• Contiguous Lead Groupings & Coronary Vessel Localization:

• NSTEMI / Unstable Angina ECG Criteria: Absence of persistent ST elevation. Characteristic findings include:
  • Horizontal or downsloping ST-segment depression $\ge 0.5\text{ mm}$ (0.05 mV) in two contiguous leads.
  • Symmetric T-wave inversion $\ge 1\text{ mm}$ (0.1 mV) in leads with prominent R waves.
  • Normal or non-specific ECG (observed in up to 30% of NSTEMI cases, reinforcing the necessity of serial troponin sampling).

Comprehensive ACS Comparison

---

3. Acute Emergency Pharmacotherapy: The FONA / MONA Regimen

The immediate emergency pharmacological management of suspected or confirmed ACS follows the mnemonic FONA (or classic MONA): Fentanyl / Morphine, Oxygen, Nitrates, and Aspirin / Antiplatelets.

+---------------------------------------------------------------------------------+
|                       EMERGENCY ACS PHARMACOTHERAPY: FONA                       |
+---------------------------------------------------------------------------------+
| [F] FENTANYL / MORPHINE : IV 2.5-5 mg Morphine (or 25-50 mcg Fentanyl) titrated |
|                          for ischemic pain. Blunts sympathetic surge.           |
|                          Co-prescribe IV antiemetic (metoclopramide/ondansetron).|
| [O] OXYGEN              : RESTRICT TO SpO2 < 94% (or < 88% in COPD).            |
|                          Hyperoxia causes coronary vasoconstriction & worsens   |
|                          infarct size. DO NOT administer routinely.             |
| [N] NITRATES            : Sublingual GTN 400 mcg spray every 5 min (max 3 doses).|
|                          MANDATORY CHECKS: SBP > 90 mmHg, HR 50-100 bpm,        |
|                          NO PDE-5 inhibitors (sildenafil <24h, tadalafil <48h),  |
|                          NO suspected right ventricular infarction (V4R).       |
| [A] ANTIPLATELETS (DAPT): ASPIRIN 300 mg chewed/dispersed immediately           |
|                          PLUS TICAGRELOR 180 mg (or Clopidogrel 300-600 mg).    |
+---------------------------------------------------------------------------------+

1. Oxygen Therapy: The Evidence Against Routine Hyperoxia

• Current Guideline Mandate: Oxygen must not be administered routinely to patients with uncomplicated ACS whose peripheral capillary oxygen saturation (SpO2) is $\ge 94%$.
• Pathophysiological Rationale: Historical practice of providing routine high-flow oxygen has been overturned by randomized clinical trials (e.g., AVOID, DETO2X-AMI). Inducing normobaric hyperoxia triggers potent reactive oxygen species (ROS) production, causes direct coronary arteriolar vasoconstriction, reduces coronary blood flow, increases coronary vascular resistance, and paradoxically increases myocardial infarct size and mortality.
• Indications: Supplemental oxygen is strictly indicated only when:
  • $\text{SpO}_2 < 94%$ on room air, or
  • The patient exhibits marked respiratory distress, acute pulmonary edema, cyanosis, or hemodynamic shock.
  • Target SpO2: Maintain between 94% and 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure, such as severe COPD).

2. Nitrates: Glyceryl Trinitrate (GTN)

• Mechanism of Action: GTN is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing intracellular cyclic guanosine monophosphate (cGMP). This produces profound systemic venodilation (reducing venous return, left ventricular end-diastolic pressure, and myocardial wall tension [preload reduction]) and direct coronary artery vasodilation (relieving coronary spasm and improving collateral flow).
• Dosing & Route: Sublingual GTN spray 400 micrograms (1 spray) administered under the tongue every 5 minutes as needed, up to a maximum of 3 doses (1,200 mcg total) over 15 minutes, while reassessing pain and hemodynamic parameters.
• Critical Contraindications & Clinical Traps:
  • Hypotension: Systolic Blood Pressure (SBP) $<90\text{ mmHg}$ (or a drop $>30\text{ mmHg}$ from baseline).
  • Severe Bradycardia or Tachycardia: Heart rate $<50\text{ bpm}$ or $>100\text{ bpm}$ in the absence of heart failure.
  • Phosphodiesterase-5 (PDE-5) Inhibitor Use: Concomitant administration of sildenafil (Viagra) or vardenafil within the preceding 24 hours, or tadalafil (Cialis) within the preceding 48 hours. PDE-5 inhibitors prevent cGMP breakdown; combining them with nitrates triggers profound, synergistic intracellular cGMP accumulation, causing catastrophic vasodilatory collapse, refractory hypotension, and cardiac arrest.
  • Right Ventricular (RV) Infarction: In patients with inferior STEMI, ischemic involvement of the right ventricle impairs RV contractility, making cardiac output critically dependent on adequate right-sided filling pressures (preload). Administering nitrates drops venous return, precipitating severe cardiogenic shock. Prior to giving nitrates in inferior STEMI, obtain right-sided chest leads (V3R, V4R) to exclude RV infarction.

3. Analgesia: Intravenous Opioids

• Drug of Choice: Intravenous Morphine Sulfate (2.5 to 5 mg IV, titrated slowly every 5 to 15 minutes) or Intravenous Fentanyl (25 to 50 micrograms IV).
• Clinical Benefit: Relieves intolerable pain, alleviates anxiety, and blunts excessive sympathetic nervous system activation, thereby reducing circulating catecholamines, heart rate, systemic vascular resistance, and myocardial oxygen consumption ($MVO_2$). Morphine also provides mild venodilatory effects, assisting in pulmonary decongestion.
• Nursing Safeguards: Opioids induce nausea, vomiting (which elevates vagal tone and intracranial/intrathoracic pressure), and respiratory depression. Always co-prescribe an intravenous antiemetic: Metoclopramide 10 mg IV or Ondansetron 4 mg IV. Have IV Naloxone (0.4 mg) immediately accessible in the clinical area.

4. Dual Antiplatelet Therapy (DAPT) & Anticoagulation

• Aspirin (Acetylsalicylic Acid): Loading dose of 300 mg orally, chewed or dispersed in water (to accelerate buccal mucosal absorption and achieve rapid platelet inhibition within 15–30 minutes), followed by a maintenance dose of 75 mg daily indefinitely. Irreversibly acetylates platelet cyclooxygenase-1 (COX-1), permanently suppressing thromboxane A2 synthesis for the 7-to-10-day lifespan of the platelet.
• Second Antiplatelet Agent (P2Y12 Receptor Antagonist):
  • STEMI / pPCI Setting: Ticagrelor 180 mg loading dose orally (followed by 90 mg twice daily), or Prasugrel 60 mg loading dose orally (followed by 10 mg daily). Ticagrelor is a direct-acting, reversible P2Y12 inhibitor with faster and more consistent platelet inhibition than clopidogrel.
  • Alternative / Fibrinolysis Setting: Clopidogrel 300 mg loading dose orally (or 600 mg if undergoing urgent PCI; 75 mg loading dose in patients $\ge 75$ years receiving fibrinolysis), followed by 75 mg daily.
• Parenteral Anticoagulation:
  • In STEMI undergoing primary PCI: Intravenous Unfractionated Heparin (UFH) bolus (70–100 units/kg) titrated to an activated clotting time (ACT) of 250–300 seconds.
  • In NSTEMI / UA: Subcutaneous Fondaparinux (2.5 mg daily) (selective Factor Xa inhibitor exhibiting the lowest bleeding risk profile) or subcutaneous Enoxaparin (1 mg/kg twice daily).

---

4. Reperfusion Pathways & Post-PCI Nursing Interventions

In acute STEMI, "time is muscle." The definitive therapeutic objective is immediate restoration of epicardial coronary blood flow (TIMI grade 3 flow) to salvage ischemic myocardium.

+-----------------------------------------------------------------------------+
|                        STEMI REPERFUSION DECISION PATHWAY                   |
+-----------------------------------------------------------------------------+
|                       DIAGNOSIS OF STEMI (ECG Confirmed)                    |
|                                     │                                       |
|                                     ▼                                       |
|               CAN PRIMARY PCI BE DELIVERED WITHIN 120 MINUTES?              |
|                           (From STEMI Diagnosis)                            |
|                                     │                                       |
|                   ┌─────────────────┴─────────────────┐                     |
|                  YES                                  NO                    |
|                   ▼                                   ▼                     |
|           PRIMARY PCI PROTOCOL                SYSTEMIC FIBRINOLYSIS         |
|      - Activate Cardiac Cath Lab          - Administer weight-adjusted      |
|      - Door-to-Balloon < 90 mins            IV Tenecteplase within 30 min   |
|      - Radial access preferred            - Monitor for reperfusion or bleed|
|      - DAPT + IV Heparin                  - Transfer immediately to PCI ctr |
+-----------------------------------------------------------------------------+

Primary Percutaneous Coronary Intervention (pPCI)

• First-Line Gold Standard: Primary PCI is the treatment of choice for STEMI provided it can be performed within 120 minutes of STEMI diagnosis by an experienced team. The benchmark hospital quality metric is a Door-to-Balloon Time $<90\text{ minutes}$ (from hospital arrival to intracoronary balloon inflation/wire crossing).
• Vascular Access: Transradial artery access is strongly recommended over transfemoral access due to significantly reduced major bleeding complications, absence of retroperitoneal hematoma risk, faster ambulation, and reduced 30-day all-cause mortality.

Fibrinolytic (Thrombolytic) Therapy

• Indication: If primary PCI cannot be delivered within 120 minutes of diagnosis (e.g., remote geographical locations or prolonged inter-hospital transfer across rural Ireland), the patient must receive systemic fibrinolysis within 30 minutes of medical contact ("Door-to-Needle Time $<30\text{ minutes}$).
• Agent: Tenecteplase (TNK-tPA) administered as a single intravenous weight-adjusted bolus over 5 to 10 seconds (alongside aspirin, clopidogrel, and enoxaparin). Tenecteplase is a genetically engineered mutant tissue plasminogen activator (tPA) with high fibrin specificity and resistance to plasminogen activator inhibitor-1 (PAI-1).
• Contraindications to Fibrinolysis:
  • Absolute: Previous intracranial hemorrhage at any time; ischemic stroke within 6 months; known central nervous system neoplasm or arteriovenous malformation; major trauma, surgery, or head injury within the preceding 3 weeks; active gastrointestinal bleeding within the past month; known bleeding disorder; suspected aortic dissection; non-compressible vascular punctures within 24 hours (e.g., liver biopsy, lumbar puncture).
  • Relative: Refractory hypertension (SBP $>180\text{ mmHg}$ or DBP $>110\text{ mmHg}$); current therapeutic oral anticoagulation; prolonged or traumatic CPR; pregnancy.
• Rescue PCI: If fibrinolysis fails to achieve reperfusion within 60 to 90 minutes (evidenced by failure of ST elevation to resolve by $>50%$ on repeat 12-lead ECG, persistent hemodynamic instability, or worsening pain), the patient must immediately undergo emergency rescue PCI.

Post-PCI Nursing Care & Vascular Sheath Management

Following PCI, the RGN is responsible for vital sign monitoring, sheath care, and detecting vascular complications:

1. Vascular Access Site Monitoring:
   • Radial Compression Device (TR Band): Inspect the wrist puncture site for bleeding or expanding hematoma every 15 minutes for the first hour, every 30 minutes for the second hour, then hourly. Check radial artery patency, thumb capillary refill ($<2\text{ seconds}$), skin temperature, and pulse oximeter waveform on the ipsilateral thumb. Perform gradual controlled deflation of the pneumatic band according to hospital protocol (typically removing 1–2 mL of air every 15–30 minutes) over 2 to 4 hours. Instruct the patient not to bend, twist, or push up from the bed using the affected wrist.
   • Femoral Sheath / Manual Compression / Closure Device: Maintain strict supine bed rest with the affected leg straight for 4 to 6 hours post-manual compression (or 2 hours following an approved vascular closure device like Angio-Seal or Perclose). Keep the head of the bed elevated $\le 30^\circ$ to prevent femoral artery angulation and shearing.
2. Monitoring for Major Vascular Complications:
   • Puncture Site Hematoma: Rapidly expanding subcutaneous swelling. Nursing action: Apply firm, continuous manual pressure 2 cm proximal to the skin puncture site (over the arteriotomy) for a minimum of 15 to 20 minutes; mark the hematoma border with a surgical skin pen; alert the interventional cardiologist.
   • Retroperitoneal Hematoma: A catastrophic occult hemorrhage occurring when femoral arterial puncture is performed above the inguinal ligament into the posterior wall. Classic presentation: Sudden unexplained arterial hypotension, resting tachycardia, flank or lower back pain, pallor, and diaphoresis without visible external bleeding. Nursing action: Lay patient flat, establish wide-bore IV access, administer rapid crystalloid resuscitation, send urgent crossmatch, and obtain emergency non-contrast abdominal/pelvic CT.
   • Pseudoaneurysm & Arteriovenous (AV) Fistula: Pseudoaneurysm presents as a painful, pulsatile mass with an audible systolic bruit on auscultation. AV fistula presents with a continuous machinery bruit and limb edema.
3. Distal Neurovascular Limb Perfusion Checks:
   • Assess the 6 Ps: Pain, Pallor, Pulselessness, Paresthesia, Paralysis, and Perishing Cold.
   • Palpate and mark distal pulses (radial for wrist access; dorsalis pedis and posterior tibial for femoral access) before and after the procedure.

---

5. Heart Failure: Pathophysiology & Clinical Distinctions

Heart Failure (HF) is a complex clinical syndrome characterized by cardinal symptoms (dyspnea, fatigue, peripheral edema) resulting from structural or functional abnormalities of the myocardium, causing elevated intracardiac pressures or reduced cardiac output at rest or during stress.

Ejection Fraction Classifications (ESC Guidelines)

• HFrEF (Heart Failure with Reduced Ejection Fraction): Left Ventricular Ejection Fraction (LVEF) $<40%$. Characterized by systolic dysfunction, impaired myocardial contractility, eccentric ventricular remodeling, and progressive chamber dilatation (most commonly secondary to ischemic cardiomyopathy post-MI or dilated cardiomyopathy).
• HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): LVEF 41% to 49%. Represents a transitional phenotypic group with mixed features.
• HFpEF (Heart Failure with Preserved Ejection Fraction): LVEF $\ge 50%$. Characterized by diastolic dysfunction—impaired ventricular relaxation, increased myocardial stiffness, and elevated left ventricular end-diastolic filling pressures despite normal global contractility (strongly linked to advanced age, female sex, longstanding arterial hypertension, atrial fibrillation, and obesity).

Neurohormonal Maladaptation in Heart Failure

When cardiac output falls, the body activates compensatory neurohormonal pathways that initially maintain perfusion to vital organs but rapidly become profoundly maladaptive, accelerating progressive myocardial failure:

+---------------------------------------------------------------------------------+
|                   NEUROHORMONAL PATHOPHYSIOLOGY OF HEART FAILURE                |
+---------------------------------------------------------------------------------+
|                          MYOCARDIAL INJURY / DYSFUNCTION                        |
|                                    │                                            |
|                                    ▼                                            |
|                         DECREASED CARDIAC OUTPUT                                |
|                                    │                                            |
|         ┌──────────────────────────┴──────────────────────────┐                 |
|         ▼                                                     ▼                 |
|  BARORECEPTOR UNLOADING                             RENAL HYPOPERFUSION         |
|         │                                                     │                 |
|         ▼                                                     ▼                 |
|  SYMPATHETIC NERVOUS SYSTEM                         RENIN-ANGIOTENSIN-          |
|  (SNS) HYPERACTIVATION                              ALDOSTERONE SYSTEM (RAAS)   |
|         │                                                     │                 |
|  • Circulating Norepinephrine ↑                     • Renin -> Angiotensin I     |
|  • Tachycardia & Inotropy ↑                         • ACE -> Angiotensin II     |
|  • Systemic Vasoconstriction ↑                      • Aldosterone Secretion     |
|  • Arrhythmias & Beta-1 Receptor Downregulation     • Sodium & Water Retention  |
|         │                                                     │                 |
|         └──────────────────────────┬──────────────────────────┘                 |
|                                    │                                            |
|                                    ▼                                            |
|           MYOCARDIAL HYPERTROPHY, FIBROSIS, APOPTOSIS & REMODELING              |
|                                    │                                            |
|                                    ▼                                            |
|                VENTRICULAR WALL STRETCH & ELEVATED PRESSURES                    |
|                                    │                                            |
|                                    ▼                                            |
|                    B-TYPE NATRIURETIC PEPTIDE (BNP) RELEASE                     |
|                    (Endogenous compensatory natriuresis & vasodilation)         |
+---------------------------------------------------------------------------------+

1. Renin-Angiotensin-Aldosterone System (RAAS): Reduced renal arterial perfusion pressure stimulates juxtaglomerular cells to secrete renin. Renin cleaves hepatic angiotensinogen into angiotensin I, which is converted by pulmonary endothelial Angiotensin-Converting Enzyme (ACE) into Angiotensin II. Angiotensin II triggers potent arteriolar vasoconstriction (increasing afterload) and stimulates the adrenal cortex to secrete Aldosterone. Aldosterone promotes sodium and water reabsorption in the renal distal convoluted tubule and collecting duct, expanding circulating blood volume (increasing preload) while wasting potassium and magnesium. Angiotensin II and aldosterone also directly drive myocardial interstitial fibrosis, myocyte apoptosis, and ventricular remodeling.
2. Sympathetic Nervous System (SNS): Carotid and aortic arch baroreceptors detect diminished stroke volume, withdrawing parasympathetic tone and triggering massive sympathetic outflow. Circulating epinephrine and norepinephrine stimulate myocardial beta-1 adrenergic receptors, increasing heart rate and contractility, while alpha-1 stimulation causes peripheral vasoconstriction. Over time, excessive catecholamine exposure induces beta-1 receptor downregulation, cardiomyocyte toxicity, and lethal ventricular arrhythmias.
3. Natriuretic Peptides (BNP & NT-proBNP): In response to increased ventricular wall tension and volume overload, cardiac myocytes synthesize and secrete B-type Natriuretic Peptide (BNP) and its biologically inactive N-terminal cleavage fragment NT-proBNP. These peptides promote natriuresis, diuresis, systemic vasodilation, and RAAS inhibition. In clinical practice, plasma concentrations serve as objective diagnostic biomarkers:
   • Acute Heart Failure Rule-Out Benchmarks: $\text{BNP} < 100\text{ pg/mL}$ or $\text{NT-proBNP} < 300\text{ pg/mL}$ reliably rules out acute decompensated heart failure with high negative predictive value.

Left-Sided vs. Right-Sided Heart Failure: Clinical Comparison

---

6. Pharmacotherapy: The Four Pillars of HFrEF & Acute Decongestion

Modern management of chronic HFrEF is founded on Guideline-Directed Medical Therapy (GDMT), specifically the "Four Pillars" proven in clinical trials to reduce all-cause mortality, decrease cardiovascular hospital admissions, and reverse adverse ventricular remodeling.

+---------------------------------------------------------------------------------+
|                    THE FOUR PILLARS OF GDMT FOR HFrEF (ESC 2021)                |
+---------------------------------------------------------------------------------+
| 1. ARNI / ACEi / ARB        : Sacubitril/Valsartan (preferred) or Ramipril.     |
|                              *MANDATORY: 36-hour washout when switching from ACEi|
| 2. BETA-BLOCKER             : Bisoprolol, Carvedilol, or Metoprolol Succinate.  |
|                              Introduce when euvolemic; titrate every 2-4 weeks. |
| 3. MRA                      : Spironolactone or Eplerenone.                     |
|                              Monitor potassium (risk of K+ > 5.0 mmol/L).       |
| 4. SGLT2 INHIBITOR          : Dapagliflozin or Empagliflozin.                   |
|                              Efficacious with or without Type 2 Diabetes.       |
| ─────────────────────────────────────────────────────────────────────────────── |
| SYMPTOMATIC DECONGESTION    : LOOP DIURETICS (Furosemide / Bumetanide)           |
|                              Titrate to achieve dry euvolemic weight.           |
+---------------------------------------------------------------------------------+

The Four Pillars of GDMT

1. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) / ACE Inhibitors:
   • Sacubitril/Valsartan (ARNI): First-line agent. Sacubitril inhibits the neutral endopeptidase enzyme neprilysin, preventing the breakdown of endogenous natriuretic peptides, bradykinin, and adrenomedullin; valsartan selectively blocks the angiotensin II type 1 (AT1) receptor. Reduces mortality and hospitalization superior to ACE inhibitors alone.
   • CRITICAL CLINICAL SAFETY RULE (36-Hour Washout): When switching an adult patient from an ACE inhibitor (e.g., ramipril, enalapril) to an ARNI (sacubitril/valsartan), the RGN must ensure a mandatory 36-hour washout period between the last dose of the ACE inhibitor and the first dose of the ARNI. Both classes inhibit bradykinin degradation; simultaneous or overlapping administration causes profound bradykinin accumulation, precipitating life-threatening angioedema and airway obstruction.
   • Alternative: ACE inhibitors (Ramipril) or ARBs (Candesartan) if ARNI is not tolerated or contraindicated.
2. Evidence-Based Beta-Adrenergic Blockers:
   • Agents: Bisoprolol, Carvedilol, or Metoprolol Succinate (long-acting). (Atenolol and short-acting metoprolol tartrate do not confer mortality benefits in heart failure).
   • Administration Principles: Beta-blockers must never be initiated during an acute, unstable decompensation with overt fluid congestion, as their negative inotropic effect can precipitate cardiogenic shock. Initiate at very low doses only when the patient is stable and euvolemic ("start low, go slow"), titrating upward every 2 to 4 weeks toward target trial doses.
3. Mineralocorticoid Receptor Antagonists (MRAs):
   • Agents: Spironolactone (25–50 mg daily) or Eplerenone (selective MRA with fewer anti-androgenic side effects like gynecomastia).
   • Action & Monitoring: Competitively blocks aldosterone receptors in the renal collecting duct and myocardium, inhibiting sodium retention and preventing cardiac collagen deposition/fibrosis. Requires close monitoring of serum potassium and renal profile: withhold or halve the dose if serum potassium exceeds 5.0 mmol/L or creatinine rises significantly.
4. Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors:
   • Agents: Dapagliflozin (10 mg daily) or Empagliflozin (10 mg daily).
   • Action: Promotes renal glucosuria and osmotic natriuresis, improves myocardial energetics, reduces cardiac preload and afterload, and confers renal protection. Proven to significantly reduce cardiovascular mortality and HF hospitalizations in all HFrEF patients, regardless of whether they have diabetes mellitus.

Acute Decongestion: Loop Diuretics

• Agents: Intravenous Furosemide (40–80 mg IV bolus or continuous infusion) or Bumetanide (1–2 mg IV).
• Mechanism: Reversibly inhibits the $Na^+-K^+-2Cl^-$ cotransporter in the thick ascending limb of the loop of Henle, blocking the reabsorption of 20–25% of filtered sodium and water, producing powerful diuresis.
• Nursing Management: Monitor urine output hourly; assess fluid balance charts; observe for hypokalemia ($K^+ < 3.5\text{ mmol/L}$), hypomagnesemia, hyponatremia, metabolic alkalosis, and pre-renal azotemia (rising urea/creatinine ratio). Loop diuretics relieve congestive symptoms but do not reduce long-term mortality.

Core Nursing Interventions & Patient Self-Management

• Daily Weight Monitoring: Weigh the patient daily using the same calibrated scale, immediately upon waking, post-voiding, and prior to breakfast. Educate the patient to report a weight gain of $>1.5\text{ to }2.0\text{ kg}$ over 2 to 3 days, which signals occult sodium and water retention preceding overt clinical dyspnea by up to two weeks.
• Fluid & Sodium Restriction: Restrict oral fluid intake to 1.5 to 2.0 litres/day in moderate-to-severe heart failure or dilutional hyponatremia ($Na^+ < 130\text{ mmol/L}$). Restrict dietary sodium to $<2\text{ g/day}$ ($<5\text{ g}$ of salt), advising against table salt and processed food.
• Vaccinations: Ensure annual influenza and pneumococcal immunizations to prevent respiratory infections that trigger acute metabolic decompensation.

---

7. Clinical Pitfalls & OSCE Station Traps